The teratogenic effects of thalidomide on limbs.
Level 5 - mechanism / opinion, no new human data
Narrative and historical review examining mechanisms without systematic synthesis or new empirical data.
PubMed 30335598 · doi:10.1177/1753193418805249
What was done
This narrative and historical review summarizes the spectrum of limb defects caused by thalidomide exposure during pregnancy, reviews the current mechanistic understanding of its teratogenicity, and discusses continued teratogenic risks linked to its contemporary use for conditions such as erythema nodosum leprosum.
What was found
The abstract provides no quantitative data or specific numerical results. It qualitatively describes phocomelia—the severe reduction or loss of proximal long bones with retention of distal hand or foot structures—as the hallmark manifestation, and notes the occurrence of new cases of birth defects in Brazil following the drug's therapeutic reintroduction.
Why it matters
The review summarizes the phenotypic spectrum and biological mechanisms of thalidomide-induced limb defects while highlighting that severe embryopathy remains an active clinical concern where the drug is re-employed.
Limits
The abstract describes a narrative review rather than a systematic review. No formal search methodology, sample size, risk-of-bias assessment, or quantitative data are reported.
Cited by
- supports Thalidomide taken during pregnancy caused children to be born with limb reduction defects.